Welcome to our dedicated page for Betterlife Pharma news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on Betterlife Pharma stock.
BetterLife Pharma Inc. (OTCQB: BETRF) is an emerging biotechnology company whose news flow centers on the development of its proprietary non-hallucinogenic compounds for neuro-psychiatric and neurological disorders. Company announcements highlight scientific data, intellectual property milestones, corporate developments and financing-related transactions tied to its lead assets BETR-001 and BETR-002.
News releases frequently cover scientific and clinical pathway updates, such as preclinical results on BETR-001’s neuroplastogenic activity, mechanistic data on serotonin receptor engagement, and progress through IND-enabling studies. BetterLife also reports on regulatory interactions, including pre-IND meetings with the FDA, and outlines its expectations for future IND filings and potential human trials, as described in its own communications.
Another recurring theme in BetterLife’s news is intellectual property and partnering activity. The company has announced the grant of a composition of matter patent for BETR-001 by the USPTO and references earlier synthesis patents on 2-bromo-LSD. It also issues updates on strategic engagements, such as its agreement with Shanghai-based YAFO Capital to pursue partnering opportunities for BETR-001 in the Greater China region and participation in international life sciences and investment forums.
Investors and observers will also find corporate and capital markets updates, including board and advisory appointments, debt settlements and conversions into equity, and commentary on management share ownership and regulatory matters. Together, these news items provide a view into how BetterLife is advancing its pipeline, managing its capital structure and positioning its non-hallucinogenic neuroplastogens within the broader neuro-psychiatric treatment landscape, based on the company’s own disclosures.
BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) has engaged Pharmaceutical Solutions Ltd. as its Clinical Research Organisation for an upcoming clinical trial of AP-003, an inhaled interferon treatment for mild to moderate COVID-19 cases. Set to begin in late 2020 across various Australian sites, the trial will involve 150 participants and assess the effectiveness of AP-003 compared to a placebo. This randomized, double-blind study aims to explore the potential of AP-003 in mitigating COVID-19 symptoms and reducing hospital admissions, marking a significant step in the global fight against the pandemic.
BetterLife Pharma Inc. has partnered with VirTrial, LLC to enhance patient monitoring for its upcoming COVID-19 clinical trials in Australia, focusing on the proprietary formulation AP-003. This collaboration enables virtual visits via a secure telehealth platform, facilitating patient recruitment and retention amidst travel restrictions. The company has also signed a share purchase agreement to assign its subsidiary, Pivot Pharmaceuticals Manufacturing Corp., including its Quebec facility lease. This strategic move aims to streamline operations and focus on advancing clinical research.
BetterLife Pharma Inc. announced approval from FINRA for its securities to be quoted on the OTC Markets under the symbol BETRF. This follows the company's compliance with Rule 15c2-11, marking a significant milestone in its U.S. market entry. CEO Dr. Ahmad Doroudian highlighted the company's commitment to developing therapeutic solutions, particularly in the fight against COVID-19. BetterLife is focused on creating drug candidates that utilize interferon-based technologies to combat viral infections and cancer. The PR also includes cautionary notes regarding forward-looking statements.